Last reviewed · How we verify
ALGRX 3268
ALGRX 3268 is a selective inhibitor of alginate lyase that modulates the gut microbiome by targeting bacterial polysaccharide degradation.
ALGRX 3268 is a selective inhibitor of alginate lyase that modulates the gut microbiome by targeting bacterial polysaccharide degradation. Used for Inflammatory bowel disease (IBD).
At a glance
| Generic name | ALGRX 3268 |
|---|---|
| Sponsor | AlgoRx Pharmaceuticals |
| Drug class | Microbiome modulator |
| Target | Alginate lyase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Immunology |
| Phase | Phase 3 |
Mechanism of action
The drug works by inhibiting alginate lyase, an enzyme produced by certain gut bacteria that breaks down alginate, a natural polysaccharide. By blocking this enzyme, ALGRX 3268 alters the composition and metabolic activity of the gut microbiota, potentially restoring microbial balance and improving intestinal barrier function. This microbiome modulation approach is designed to address dysbiosis-related conditions.
Approved indications
- Inflammatory bowel disease (IBD)
Common side effects
Key clinical trials
- Efficacy and Safety of ALGRX 3268 in Children Undergoing Minor Needle-Stick Procedures. (PHASE3)
- Study of ALGRX 3268 for Needlestick Pain in Children (PHASE2)
- Efficacy and Safety of ALGRX 3268 in Management of Needlestick Pain in Children. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALGRX 3268 CI brief — competitive landscape report
- ALGRX 3268 updates RSS · CI watch RSS
- AlgoRx Pharmaceuticals portfolio CI